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NOVELTY AND IMPACT: In this first GWAS of epithelial ovarian cancer in women of African Ancestry to date, 
we report ten novel associated SNPs. Our results also provide evidence of variants for ovarian cancer that are 
shared among women of European and African Ancestry. 
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ABSTRACT 
Women of African Ancestry have lower incidence of epithelial ovarian cancer (EOC) yet worse survival 
compared to women of European Ancestry. We conducted a genome-wide association study (GWAS) in 
African ancestry women with 755 EOC cases, including 537 high-grade serous ovarian carcinomas (HGSOC), 
and 1,235 controls. We identified four novel loci with suggestive evidence of association with EOC (P<1x10-6), 
including rs4525119 (intronic to AKR1C3), rs7643459 (intronic to LOC101927394), rs4286604 (12 kb 3’ of 
UGT2A2), and rs142091544 (5 kb 5’ of WWC1). For HGSOC, we identified six loci with suggestive evidence of 
association including rs37792 (132 kb 5’ of FST), rs57403204 (81 kb 3' of MAGEC1), rs79079890 
(LOC105376360 intronic), rs66459581 (5 kb 5’ of PRPSAP1), rs116046250 (GABRG3 intronic), and 
rs192876988 (32 kb 3’ of GK2). Among the identified variants, two are near genes known to regulate 
hormones and diseases of the ovary (AKR1C3 and FST), and two are linked to cancer (AKR1C3 and 
MAGEC1). In follow-up studies of the 10 identified variants, the GK2 region SNP, rs192876988, showed an 
inverse association with EOC in European ancestry women (P=0.002), increased risk of ER positive breast 
cancer in African ancestry women (P=0.027), and decreased expression of GK2 in HGSOC tissue from African 
ancestry women (P=0.004).  A European ancestry-derived polygenic risk score showed positive associations 
with EOC and HGSOC in women of African ancestry suggesting shared genetic architecture. Our investigation 
presents evidence of variants for EOC shared among European and African ancestry women and identifies 
novel EOC risk loci in women of African ancestry.  
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INTRODUCTION 
Epithelial ovarian cancer (EOC) is a rare but deadly disease that has a slightly higher incidence in women of 
European ancestry compared to women of African ancestry.1 However, in the United States, the five-year relative 
survival is much worse for African-American women at 35% compared to 47% for European ancestry women.1 
To date, genome-wide association studies (GWAS) have identified 30 common, low penetrant EOC susceptibility 
alleles2 but due to small sample sizes of other ethnic and racial groups, most published GWAS studies of EOC 
have been restricted to European ancestry women. There have been no GWAS in women of African ancestry. 
Although there are 30 confirmed GWAS SNPs that have been reported in European ancestry women, it is 
unknown whether there is any concordance among women of African descent. 
 
 The Genetic Associations and Mechanisms in Oncology (GAME-ON) network designed a custom Illumina 
array, the OncoArray, in order to replicate previous GWAS findings and identify new cancer susceptibility loci.3 
The OncoArray includes ~533,000 variants (of which 260,660 formed a GWAS backbone) and was used for 
coordinated genotyping of over 400,000 cancer cases and controls, including EOC case-control studies of the 
Ovarian Cancer Association Consortium (OCAC) and the multi-center African-American Cancer Epidemiology 
Study (AACES).4 The present study conducted a GWAS in 755 EOC cases and 1,235 controls of African 
ancestry from the OCAC and AACES. To increase the sample size, additional genotype data were combined 
from the OCAC Collaborative Oncological Gene-environment Study (COGS) and three EOC GWAS5 to 
evaluate the concordance of confirmed GWAS SNPs found in women of European ancestry. We present the 
results of these association analyses together with expression quantitative trait locus (eQTL) analyses for 
SNPs reaching a suggestive threshold of P<1x10-6. The functional annotation of the EOC susceptibility loci in 
women of African Ancestry is described. 
 
MATERIALS AND METHODS 
Study samples 
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All subjects included in this analysis were of African descent and provided written informed consent as well as 
data and blood samples under ethics committee-approved protocols. 
The GAME-ON OncoArray data set comprised 63 OCAC studies and the AACES.4  The analyses for this study 
were restricted to 32 studies that contributed samples from individuals of African descent (Supplementary Table 
1).   
Genotype data and Quality Control (QC) 
Genotyping was performed at five genotyping centers: University of Cambridge, Center for Inherited Disease 
Research (CIDR), National Cancer Institute (NCI), Genome Quebec and Mayo Clinic. OncoArray sample QC for 
the genotypes received from Cambridge was similar to that carried out for the other projects that used the 
OncoArray as described in Pharoah et al. 2013.3  Samples were excluded if the genotyping call rate was < 95%, 
for high or low heterozygosity, if the individual was not female or had ambiguous sex, or were duplicates. SNP 
QC was carried out according to the OncoArray QC guidelines.3  Sample level QC included restriction to female 
samples, as well as check for call rate > 95%, heterozygosity (either too big or too small), removal of ineligible 
samples, and relationship inference to check for unexpected first-degree relatives. SNP level QC included filter 
on call rate > 95% and Hardy-Weinberg Equilibrium p-value > 1x10-5. After applying these filters for QC, there 
were 466,142 SNPs remaining for 2,088 samples (832 EOC cases and 1,255 controls). 
Genetic ancestry analysis 
Intercontinental ancestry was calculated for the OCAC and AACES samples using the software package 
FastPop6 (http://sourceforge.net/projects/fastpop/) that was developed specifically for the OncoArray 
Consortium. Only the African ancestry samples, defined as having >50% African ancestry, were used for the 
GWAS reported here (755 EOC cases and 1235 controls). Among the cases, 537 were high-grade serous 
ovarian carcinoma (HGSOC), 21 low-grade serous, 31 endometrioid, 24 clear cell, 51 mucinous 12 mixed cell, 
65 other EOC, and 14 with missing histotype. Principal components computed using FastPop6 were further used 
to adjust for population structure in our GWAS. 
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Genome-wide Imputation of genotypes 
Using the genotyped SNPs that passed quality control, haplotypes were phased with SHAPEIT v27 followed by 
imputation to the 1,000 Genomes Phase 3 v5 reference set8 using Minimac3.9 
Association analyses in ovarian cancer cases and controls of African descent  
Genome-wide association analysis was performed by logistic regression with adjustment for two principal 
components of ancestry using a score test to account for genotype uncertainty as implemented in 
SNPTESTv2.5.2.10 For genotyped SNPs, we included results only for those SNPs with Hardy-Weinberg 
Equilibrium p-value > 1x10-5 and heterozygosity count (HC) > 30, where HC is defined as N x MAF x (1-MAF) 
for each SNP, N represents the sample size (either the number of cases or the number of controls), and MAF 
represents the SNP minor allele frequency. For imputed SNPs, we included those SNPs with imputation R-
squared > 0.5, and effective heterozygosity count (effHC) > 30, where effHC is defined as the imputation R-
squared x HC. Note that we applied quality control filters separately for cases and controls to select SNPs carried 
forward for genetic association analysis, such that a minimum HC (or effective HC) of 30 was observed among 
each of the case and control groups.  After applying these filters, there were 12,486,624 and 11,083,029 SNPs 
remaining in the GWAS of EOC and HGSOC, respectively. We examined quantile-quantile plots for the SNPs 
remaining after applying filters (Supplementary Figure 1), and obtained lambdas of 1.01 in both the EOC and 
HGSOC analyses, indicating that our analyses were free from obvious inflation in the distribution of observed p-
values. We caclulated Bayesian false-discovery probabilities (BFDPs) for associated SNPs assuming prior 
probabilities of association 1:1,000 and1:10,000 to facilitate interpretation of the reported SNP associations.11 
 
Expression quantitative trait locus (eQTL) analysis for selected GWAS SNPs 
We pursued eQTL analysis using gene expression measurements from formalin-fixed paraffin-embedded 
(FFPE) tissue specimens collected from the facility where the cytoreductive surgery was performed for 260 
African ancestry HGSOC cases in the AACES and a case-control study in OCAC, the North Carolina Ovarian 
Cancer Study (NCOCS). RNA was extracted using the Qiagen AllPrep DNA/RNA FFPE isolation reagents in 
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conjunction with the Qiagen GeneRead kit, and RNA was assayed on Affymetrix Human Transcriptome 2.0 ST 
GeneChips. R (version 3.5.2) Bioconductor (version 3.8) was used to quantitate expression levels for targeted 
genes. We used robust multi-array average (RMA) from the oligo package (target=”core”) to normalize the 
expression intensities12 and ComBat (Bioconductor-sva) to remove batch effects.13 We then mapped probe 
intensity measurements to gene identifiers14 before generating box plots of expression distributions by genotype. 
For each of the ten SNPs identified in the GWAS of EOC and HGSOC (Table 1), we examined genes and 
transcripts within the region of identified GWAS SNPs for eQTL evidence using an additive model with 
adjustment for age and the first two principal components of ancestry. For the selected transcripts, we report all 
eQTL associations demonstrating nominal statistical significance at P<0.05 for available transcripts falling within 
the region of identified GWAS SNPs. 
Examination of pleiotropy of GWAS SNPs associated with EOC in women of African Ancestry with breast 
and prostate cancer in African ancestry individuals 
Because we were unable to identify other GWAS of EOC in women of African ancestry, independent validation 
of GWAS results was not possible. Therefore, we examined the association of the ten SNPs identified in the 
present African ancestry GWAS of EOC or HGSOC at P<1x10-6 (Table 1) with previously completed studies of 
breast cancer (overall, ER positive and ER negative) and prostate cancer in populations of African descent. 
Genetic associations in breast cancer were determined from 3,007 cases, of which 987 are ER negative and 
1,518 are ER positive, and 2,720 African ancestry controls from the African American Breast Cancer Consortium 
(AABC), using the Illumina Human 1M-Duo BeadChip.15 The genotype associations for prostate cancer were 
from 4,853 cases and 4,678 controls in the African American Prostate Cancer Consortium (AAPC), using the 
Illumina Infinium 1M-Duo.16 For the selected SNPs, evidence of association from the studies of breast and 
prostate cancer is reported at a nominal level (P<0.05) without adjustment for multiple comparisons. 
 
Concordance of associated SNPs across women of African and European ancestry  
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We examined whether susceptibility genes for EOC previously identified in European ancestry women2 were 
associated with EOC among women of African ancestry as well as whether the loci identified among women of 
African ancestry in this analysis were associated with EOC among European ancestry women.  
Fine mapping of gene regions was performed for (1) the loci previously identified as significantly associated with 
EOC in European ancestry women among African ancestry women and (2) the loci identified as significantly 
associated with EOC in those of African Ancestry in the present analysis among European ancestry women. 
Plots were generated for each region defined by the position of the most strongly associated SNP +/- 400 kb 
using the LocusZoom software with the hg19/1000 Genomes Nov 2014 AFR (or EUR depending on the ethnic 
population) as the reference panel for linkage disequilibrium information. Significance for each region of interest 
was defined by both a Bonferroni threshold (alpha-level of 0.05/number of SNPs tested in that region) and a 
more conservative, suggestive threshold (alpha-level of 0.05/(number of SNPs tested in that region/3)). To 
further examine the global genetic architecture in the two populations, we calculated a polygenic risk score using 
24 SNPs from published GWAS of ovarian cancer in European ancestry women, excluding SNPs associated 
only with mucinous tumors.3,17 
Data Availability 
GWAS data that support the findings of this study will be openly available in dbGaP, URL and accession 
number are still to be determined. Other portions are not publicly available due to privacy or ethical restrictions. 
 
RESULTS 
Genome-wide association of EOC and HGSOC in African ancestry women 
Genetic association analyses were performed using genotype data from 755 invasive EOC cases (537 HGSOC) 
and 1,235 controls of African ancestry from OCAC and AACES.  The numbers of participants by study for OCAC 
are shown in Supplementary Table 1. The Manhattan plots from the GWAS in African ancestry women for both 
overall EOC and HGSOC are shown in Supplementary Figure 2. We did not observe any genetic markers that 
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were statistically significantly associated with EOC or HGSOC risk at the standard genome-wide significance 
level of P<5x10-8.  
 
Using a suggestive threshold of P<1x10-6, we identified four distinct loci for association with EOC and six distinct 
loci for HGSOC (Table 1). The four loci associated with EOC included 10p15.1 (lead SNP rs4525119, intronic 
to AKR1C3, P=4.9 x 10-7, effect allele frequency [EAF]=0.33), 3p25.3 (lead SNP rs7643459, intronic to 
LOC101927394, P=8.4 x 10-7, EAF=0.36), 4q13.3 (lead SNP rs4286604, 12 kb 3’ of UGT2A2 P=8.5x10-7, 
EAF=0.27), and 5q34 (lead SNP rs142091544, 5 kb 5’ of WWC1, P=9.4 x 10-7, EAF=0.03). Of these four loci, 
none reached the threshold of P<1x10-6 for HGSOC, although a p-value of 1.4 x10-6, just below this threshold, 
was found for rs764359 (OR=1.45; 95% CI: 1.25-1.68).  The six loci associated with HGSOC included 5q11.2 
(lead SNP rs37792, 132 kb 5’ of FST (Follistatin), P=6.0x10-8, EAF=0.34), Xq27.2 (lead SNP rs57403204, 81 kb 
3' of MAGEC1, P=1.7x10-7, EAF=0.06), 10p15.1 (lead SNP rs79079890, LOC105376360 intronic, P=3.0x10-7, 
EAF=0.03), 17p25.1 (lead SNP rs66459581, 5 kb 5’ of PRPSAP1, P=5.1x10-7, EAF=0.23), 15p12 (lead SNP 
rs116046250, GABRG3 intronic, P=8.7x10-7, EAF=0.05), and 4q21.21 (lead SNP rs192876988, 32 kb 3’ of GK2, 
P=9.2x10-7, EAF=0.05). The regional association plots for these ten SNPs are shown in Supplementary Figure 
3 (EOC) and Supplementary Figure 4 (HGSOC).  For the four loci associated with EOC overall, the BFDP 
ranged from 5% to 8% assuming a prior of 1:1,000 (Table 1) For the six loci associated with HGSOC the BFDP 
ranged from <1%-8% assuming a prior of 1:1,000 (Table 1). Assuming a prior probability of 1:10,000, we 
identified one locus for HGSOC with a BFDP<5% (FST rs37792, BFDP=4%; Supplementary Table 2).  
  
Expression quantitative trait locus (eQTL) analysis for GWAS SNPs 
Results of eQTL analyses on 260 HGSOC tissue samples from women of African ancestry for each of the ten 
EOC- and HGSOC-associated regions of interest are in Figure 1. We identified the set of genes lying within a 
+/- 100kb region of the most strongly associated SNP for each locus to pursue for the eQTL analysis. For one 
SNP, rs37792, there were no genes or transcripts identified within a +/- 100 kb region, so we expanded 
consideration to a +/- 500 kb region that included FST and three other genes (Supplementary Table 3). Among 
the gene and transcript targets selected for follow-up, expression data were available for 21 genes and 
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transcripts falling within the regions of seven GWAS SNPs. We note that we did not have expression data 
available for the non-coding transcripts identified within the regions of two SNPs (rs7643459 and rs79079890), 
so these SNPs and transcripts could not be carried forward for eQTL analysis. Among the SNPs and transcripts 
examined in eQTL analyses, we identified a significant association for rs192876988, where carriers of allele C 
showed decreased expression of GK2 (P=0.004, Figure 1 and Supplementary Figure 5). We also identified a 
nominally significant association for rs37792 (P=0.03).  
 
Breast and prostate cancer associations for selected SNPs identified in the GWAS of EOC and HGSOC 
As evidence for pleiotropy has been observed in Europeans,2 we evaluated pleiotropy with ovarian cancer 
associated SNPs among African Americans diagnosed with breast and prostate cancer in the AABC and AAPC, 
respectively. For selected SNPs from the GWAS of EOC and HGSOC in African ancestry women (Table 1), we 
examined evidence of association with breast and prostate cancer in individuals of African ancestry. The EOC-
associated LOC101927394 region SNP rs7643459 allele T demonstrated nominal evidence of association with 
increased risk of ER negative breast cancer (P=0.029) with an OR of 1.13 (95% CI 1.01, 1.26) (Supplementary 
Table 4) showing consistent direction with that reported for EOC. The same SNP rs7643459 allele T also showed 
nominal association with prostate cancer in African Americans (P=0.034; Supplementary Table 5). Within the 
region of UGT2A2, SNP rs4286604 allele A was associated with increased risk of prostate cancer (P=0.025). 
We note that the A allele for this SNP was identified as having a protective association for EOC (Table 1), 
indicating a discordant direction of association comparing the relationship with EOC versus prostate cancer. 
SNP rs142091544 allele T within the WWC1 region, associated with EOC, demonstrated evidence of association 
with ER negative breast cancer (OR=1.55, 95% CI=1.19, 2.02; P=0.001) indicating a consistent direction 
compared to the association with EOC. The LOC105377300 / GK2 region SNP rs192876988 allele C 
demonstrated nominal association with increased risk of ER positive breast cancer (OR=1.32, 95% CI=1.03, 
1.69; P=0.027; Supplementary Table 4), showing a consistent direction of effect with that reported for HGSOC 
(Table 1).  
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Concordance of associated SNPs across women of African and European ancestry   
One of the ten SNPs (LOC105377300 / GK2 region SNP rs192876988) identified to be associated in women of 
African ancestry was found to be significantly associated (P=0.002) with HGSOC at the Bonferroni threshold 
among European ancestry women, although the direction of the association was discordant with that among 
African ancestry women (Table 1). Of the 30 previously identified GWAS SNPs detected in European ancestry 
women, four SNPs were significantly associated with EOC among African ancestry women (P<0.05):  
19p13.11 (rs4808075, P=0.013), 5p15.33 (rs7705526, P=0.014), 17q21.32 (rs1879586, P=0.018), and 17q12 
(rs7405776, P=0.026) (Table 2). Combining the 24 published European ancestry GWAS SNP associations 
(omitting mucinous associated SNPs due to the small number of cases in the dataset), the association of the 
resulting polygenic risk score with EOC was 1.20 per standard deviation in polygenic risk score (95% CI = 
1.09, 1.31, P=4.46x10-9) and 1.26 per standard deviation in polygenic risk score (95% CI: 1.13, 1.39, 
P=3.02x10-11) for HGSOC, demonstrating a positive association of this European ancestry-derived risk score 
with EOC risk in women of African ancestry. These are weaker in comparison to the recently reported 
polygenic risk score for East Asian women of 1.76 per standard deviation for HGSOC (P=8.6x10-6).18 
 
The results from fine mapping of the gene regions of the thirty previously identified SNPs3 associated with 
EOC and HGSOC in European ancestry women among the sample of African ancestry women identified one 
risk region in African ancestry women that was significantly associated with EOC after Bonferroni correction, 
18q11.2 (P=1.84x10-5) (Table 3 and Supplementary Table 6). The lead SNP in that region (chr18:21555816, 
rs1258109, 8 kb 5’ of LOC105372023) is located ~150 kb from the LAMA3 region variant previously reported in 
European ancestry (chr18:21405553, rs8098244). Notably, rs8098244 demonstrates differences in MAF 
across race/ethnic groups with MAFs of 0.28 and 0.03 in the 1000 Genomes European versus African ancestry 
populations (source: HaploReg v4.1), respectively, corresponding to markedly reduced power to detect 
associations with this variant in African ancestry women. Four loci were associated with EOC at a suggestive 
threshold: 9p22.2 (chr9:16978052, rs373094273, P=2.67x10-5, 36 kb 5’ of LOC105375983), 8q21.13 
(chr8:82866267, rs1839897, P=1.44x10-5,104 kb 3’ of LOC105375928), 10q24.33 (chr10:105375295, 
rs138417137, P=3.40x10-5, SH3PXD2A intronic), and 3q22.3 (chr3:138839642, rs75623154, P=3.34x10-5, 
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BPESC1 intronic). In examination of association with HGSOC, we identified one Bonferroni-significant 
association at 8q21.13 (chr8:82866267, rs1839897, P=3.98x10-6, 104 kb 3’ of LOC105375928) located ~200 
kb from the previously reported CHMP4C region variant (chr8:82668818, rs76837345). Additionally, a locus in 
region 12q24.31 reached the suggestive threshold (chr12:121113096, rs111546208, CABP1 intronic, 
P=2.51x10-5) for association with HGSOC among African ancestry women. 
 
Of the  ten SNPs newly identified in GWAS of African ancestry women, one, the GK2 region SNP 
rs192876988, showed evidence a protective association (P=0.002) in the OCAC European ancestry GWAS 
that included up to 23,543 EOC cases and 29,444 controls (Table 1). Fine mapping of these gene regions in 
European ancestry women provided no evidence of another SNP within the region associated with EOC or 
HGSOC at the Bonferroni significance threshold; however, a SNP in the 4p13 region reached statistical 
significance at the suggestive threshold, P=1.14x10-5 (Supplementary Table 7). The lead SNP in this region 
was rs2292092 (chr4:70592790), a variant in the 3’ UTR of the SULT1B1 gene. 
 
DISCUSSION 
Here, we report on the first GWAS of EOC and HGSOC in women of African ancestry. Due to the limited 
number of EOC cases of African ancestry available for this study, we applied a suggestive threshold of 
P<1x10-6 for the current investigation. At this suggestive level of statistical significance, we identified four loci 
associated with EOC in women of African descent and six distinct and novel loci associated with HGSOC in 
women of African descent. Although one SNP was observed to be associated with HGSOC among European 
ancestry women, the direction of the association was not concordant with that of African ancestry women. 
Below we review the functional relevance of these genes to ovarian cancer and other cancers. 
The variant with the smallest p-value associated with EOC in women of African descent (rs4525119) is in an 
intron of AKR1C3, a gene which encodes an enzyme of the aldo-keto reductase superfamily.19 AKR1C3 plays 
a role in androgen biosynthesis20 and has been linked to benign gynecologic conditions, endometriosis and 
polycystic ovary syndrome (PCOS)21–24, which are risk factors for ovarian cancer. Consistent with a possible 
relationship with a predisposition to endometriosis, an OR of 1.78 (95% CI = 1.09-2.90) for the association 
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between a history of endometriosis and invasive EOC risk among African Americans was recently reported in 
the AACES.25 Another locus associated with EOC is near the WWC1 gene, which encodes the WW domain-
containing protein 1 (WWC1), also known as KIBRA, and is likely a regulator of the tumor suppressive Hippo 
signaling pathway.26 While WWC1 has been primarily linked to episodic memory and Alzheimer’s disease,27–30 
a recent candidate gene study31 observed an association between WWC1 variants and risk of estrogen-
receptor positive breast cancer in women of African ancestry. Likewise, WWC1/KIBRA has been linked to 
breast cancer outcomes, including recurrence-free survival and metastasis.32,33 In the current study, we found 
an association with ER negative breast cancer for the SNP nearest to the WWC1 gene. To our knowledge, the 
other two loci associated with EOC in women of African descent at the suggestive threshold, LOC101927394 
and UGT2A2, have not been reported in association with cancer or other diseases. However, when we 
assessed whether the rs7643459 allele T in LOC101927394 was associated with cancer in individuals of 
African descent using data from the AABC and AAPC consortium, we demonstrated a nominal association with 
risk of ER negative breast cancer and prostate cancer in African ancestry individuals.  
 
The variant with the smallest p-value for HGSOC was observed for a SNP upstream of FST (rs37792). The 
FST gene encodes a gonadal protein that inhibits the release of follicle-stimulating hormone34, and is 
consistent with the suspected hormonal etiology of ovarian cancer.35 Polymorphisms of FST have been linked 
to PCOS36 or markers for PCOS37, a risk factor for ovarian cancer.38 With potential importance to cancer risk, 
progression and survival, the second most significant HGSOC-associated gene, MAGEC1, is a member of the 
melanoma-associated antigen (MAGEs) gene family and encodes tumor-specific antigens that can be 
recognized by autologous cytolytic T-lymphocytes.39 Due to these properties, the MAGE gene family have 
garnered attention as possible targets for cancer immunotherapy.40 MAGEC1 expression has been linked to an 
improved ovarian cancer progression-free survival.41 Recently, a missense variant in MAGEC3  was reported 
to have an X-linked pattern of inheritance in ovarian cancer families.42 
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Several of the SNPs associated with EOC and HGSOC were long non-coding RNA (ncRNA) genes, 
LOC101927394, LOC105376360, and LOC105377300 (GK2). Little is known about these specific ncRNAs, but 
ncRNAs are increasingly reported by GWAS studies and are thought to play important roles in gene 
regulation.43  SNPs in long ncRNAs have been shown to contribute to the development of ovarian cancer, 
where a variant within the exonic region of a long ncRNA gene (rs17427875, HOXA11-AS) was marginally 
associated with reduced risk of serous ovarian cancer.44 We also demonstrated that LOC105377300 / GK2 
region SNP rs192876988 allele C was associated with an increased risk of ER positive breast cancer in African 
ancestry women from AABC, and inversely associated with HGSOC in European ancestry women from OCAC. 
The rs192876988 allele C also showed association with reduced expression of GK2 in HGSOC tissue samples 
from women of African ancestry. GK2 encodes glycerol kinase 2, a key enzyme in the regulation of glycerol 
uptake and metabolism, and has been associated with glycerol kinase deficiency.45 It remains unclear whether 
the association between rs192876988 and GK2 expression is mediated by the nearby ncRNA. 
 
A few SNPs were identified through fine mapping of loci previously reported in European ancestry-based 
GWAS of ovarian cancer3 that may be of importance to ovarian cancer risk among African ancestry women. 
Four of these SNPs were near or in long ncRNA genes (LOC105372023, LOC105375983, LOC105375928, 
and BPESC1), while two SNPs lie in protein coding sequences for SH3PXD2A and CABP1. The SH3PXD2A 
gene encodes an adaptor protein involved in formation of invadopodia and degradation of the extracellular 
matrix, which both contribute to tumor invasion.46 The CABP1 gene encodes a calcium binding protein that is 
highly expressed in the brain and retina, and is important in calcium mediated cellular signal transduction.47 
Through the fine mapping of gene regions among European ancestry women, we identified one SNP in the 3’ 
UTR region of the SULT1B1 gene. The SULT1B1 gene encodes a sulfotranferase enzyme that catalyzes the 
sulfate conjugation of estradiol, thyroid hormones, and drugs.48 Overall, although we identified limited statistical 
significance in examining the specific genetic variants previously reported in GWAS of European ancestry 
individuals, our fine mapping effort underscores the possibility of shared genes, pathways and biological 
mechanisms underlying risk of ovarian cancer in European and African ancestry women.  
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The OCAC and AACES provided a unique opportunity to evaluate genetic associations in African ancestry 
women with EOC as no individual study alone has enrolled enough subjects. That said, even with data pooled 
from 32 individual studies, the sample size was underpowered for detection of genome-wide significant 
associations.  As shown in Table 2, power to detect associations of SNPs confirmed among European 
ancestry in those of African ancestry was limited for most SNPs and ranged from 0.015/0.16 to 0.819/0.982 
(based on power calculations with/without consideration for multiple comparisons).  
 
There are very few existing studies that were not included in our analysis that have enrolled women of African 
descent with ovarian cancer. However, the Black Women’s Health Study (BWHS), the Women’s Health 
Initiative (WHI), and the Southern Community Cohort Study (SCCS) have EOC cases diagnosed in women of 
African descent that were not included in our analyses. Since none of these three studies has participated in 
OCAC or GAME-ON, genotype data generated from the OncoArray project were not available. Thus far, 
neither the SCCS nor the BWHS have genotyped ovarian cancers in their cohorts. Although the WHI has 
conducted genome-wide genotyping, a different genetic platform (Affymetrix 6.0 array) was used. When we 
attempted to add a small number of cases and many African ancestry controls from WHI, there were 
systematic differences in allele frequencies observed across the two platforms that precluded merging WHI 
samples with our OCAC and AACES samples without introducing false positives.49 Due to lack of available 
GWAS efforts for ovarian cancer in African ancestry women, we were unable to pursue formal replication of 
our selected GWAS SNPs. Although we successfully identified some signals of association for our identified 
SNPs in examination of independent samples of African ancestry from case-control studies of breast and 
prostate cancers, we emphasize that these efforts only allowed us to identify SNPs with shared effects across 
cancer types, without the ability to confirm any SNPs that have mechanisms specific to ovarian cancer. These 
observations underscore the need for new genotyping initiatives and new data collection that target minority 
populations with ovarian cancer. Our study included a GWAS backbone in the OncoArray that was designed 
for women of European ancestry, and therefore has reduced power for GWAS analysis in women of African 
Ancestry.  
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This GWAS is the first to report genome-wide associations for ovarian cancer in African ancestry women. Our 
findings provide suggestions of genetic association for ovarian cancer in African ancestry women.  Only one of 
the 10 SNPs associated with ovarian cancer in African ancestry women was found to be associated in 
European ancestry women, though the direction of the association was not consistent across race/ethnic 
groups, perhaps reflecting differences in linkage disequilibrium across groups. Our data show that the 
suggestive SNP associations for ovarian cancer among women of African ancestry are not generally replicated 
among women of European ancestry, which has been similarly observed for other cancers and disease states, 
such as breast cancer.50 Our results demonstrate that some ovarian cancer GWAS variants identified in 
women of European ancestry may be associated with ovarian cancer in women of African ancestry. This 
finding is further underscored by our report of statistically significant association of the polygenic risk score 
derived from published European GWAS hits with risk of EOC in women of African Ancestry. These findings 
suggest there may be some shared genetic architecture of EOC between women of European and African 
ancestry in susceptibility to ovarian cancer. Additional genetic studies leveraging larger sample sizes will be 
needed to refine genetic risk prediction and elucidate the underlying biology of EOC in African ancestry 
women.     
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Table 1: SNPs demonstrating genome-wide suggestive evidence of association in the African Ancestry 
OncoArray Analysis and comparison with results of OCAC studies of women of European ancestry  
Subtyp
e 
Nearest 
Gene 
SNP ID 
(Effect / 
other 
allele) 
Build 37 
Chr:Pos 
African Ancestry** European Ancestry3*** 
EA
F 
OR 
 (95% 
CI) 
P-
value 
BFD
Pŧ 
EA
F 
OR  
(95% 
CI) 
P-
valu
e 
EOC 
AKR1C3 rs4525119 (T/C) 
10:5091
954 
0.3
31 
0.70 
 (0.61-
0.81) 
4.9 x 
10
-7
 
8% 0.300 
1.00 
(0.97-
1.03) 
0.93
6 
LOC1019
27394 
rs764345
9* (T/G) 
3:80048
28 
0.3
62 
1.40 
 (1.22-
1.60) 
8.4 x 
10
-7
 
5% 0.421 
1.00  
(0.98-
1.03) 
0.74
2 
UGT2A2 rs4286604 (A/G) 
4:70442
165 
0.2
68 
0.69  
(0.59-
0.80) 
8.5 x 
10
-7
 
5% 0.227 
1.01  
(0.98-
1.05) 
0.42
1 
WWC1 
rs142091
544 
(T/C) 
5:16771
4000 
0.0
34 
3.22 
(2.02-
5.13) 
9.4 x 
10-7 9% 
0.0
10 
0.97 
(0.83-
1.13) 
0.66
5 
HGSO
C 
FST rs37792  (G/A) 
5:52644
647 
0.3
42 
0.65  
(0.55-
0.76) 
6.0 x 
10
-8
 
<1% 0.308 
1.03 
(0.99-
1.06) 
0.11
0 
MAGEC1 rs57403204 (G/A) 
X:14107
8552 
0.0
64 
2.62  
(1.83-
3.76) 
1.7x10
-7 1% 
0.0
13 
1.03 
(0.90-
1.18) 
0.68
2 
LOC1053
76360 
rs790798
90 (G/T) 
10:3684
148 
0.0
32 
3.20  
(2.05-
4.99) 
3.0x10
-7 3% 
0.1
31 
1.02  
(0.98-
1.08) 
0.53
4 
PRPSAP
1 
rs664595
81 (A/AC) 
17:7435
5264 
0.2
34 
1.63  
(1.35-
1.97) 
5.1x10
-7 2% 
0.0
89 
0.97  
(0.92-
1.03) 
0.37
7 
GABRG3 rs116046250 (G/T) 
15:2723
1950 
0.0
46 
2.95  
(1.92-
4.54) 
8.7x10
-7 7% --- --- --- 
LOC1053
77300 / 
GK2 
rs192876
988 (C/T) 
4:80297
251 
0.0
46 
3.01  
(1.94-
4.68) 
9.2x10
-7 8% 
0.0
14 
0.75  
(0.62-
0.90) 
0.00
2 
SNP: single nucleotide polymorphism; EAF: effect allele frequency; OR: odds ratio; CI: confidence interval; EOC: epithelial 
ovarian cancer; HGSOC: high-grade serous ovarian carcinoma. 
We show the strongest associated SNP for each locus reaching P<1x10-6 for each subtype. 
*Genotyped SNPs, if not indicated otherwise then imputed  
** African ancestry was defined as >50% African ancestry as calculated by FastPop 
*** European ancestry was defined by self-report  
ŧBFDP: Bayesian false discovery probability assuming a prior of 1:1,000 among women of African ancestry 
  
31 
 
Table 2: Association of SNPs previously identified in European Ancestry GWAS of EOC among women 
of African Ancestry  
     European Ancestry* African Ancestry** Powera 
Locus SNP ID Build 37 
Chr:Pos 
Nearest Gene Phenotype OR (95% CI) P-value MAF OR (95% CI) P-value With/Without 
Bonferroni 
correction 
Confirmed SNPs in European ancestry OncoArray meta-analysis  
1p34.3 rs58722170 1:38096421 RSPO1 Serous 1.10 (1.07-1.13) 1.4E-09 0.203 0.99 (0.85-1.17) 0.976 0.025/0.222 
2q14.1 rs752590 2:113972945 PAX8 Mucinous 1.30 (1.21-1.39) 2.2E-12 0.408 1.00 (0.88-1.15) 0.949 0.799/0.978 
2q31.1 rs711830 2:177037311 HOXD3 Mucinous 1.27 (1.20-1.35) 1.1E-14 0.114 1.10 (0.90-1.34) 0.370 0.240/0.684 
2q31.1 rs6755777 2:177043226 HAGLR Serous 1.12 (1.09-1.15) 2.7E-15 0.131 1.06 (0.88-1.28) 0.548 0.026/0.223 
3q25.31 rs62274041 3:156435640 TIPARP HGSC 1.57 (1.48-1.66) 2.1E-57 -- -- -- -- 
5p15.33 rs10069690 5:1279790 TERT Serous 1.13 (1.09-1.17) 1.5E-12 0.401 0.94 (0.83-1.08) 0.406 0.097/0.454 
5p15.33 rs7705526 5:1285974 TERT Serous borderline 1.38 (1.29-1.48) 5.5E-19 0.189 1.23 (1.04-1.45) 0.014 0.818/0.982 
8q21.13 rs76837345 8:82668818 CHMP4C HGSC 1.20 (1.13-1.28) 9.0E-10 -- -- -- -- 
8q24.21 rs1400482 8:129541931 LINC00824 Serous 1.23 (1.19-1.28) 7.4E-26 -- -- -- -- 
9p22.2 rs10962692 9:16915874 BNC2 HGSC 1.36 (1.30-1.42) 1.4E-47 0.032 0.97 (0.67-1.41) 0.875 0.087/0.431 
9q34.2 rs8176685 9:136138765 ABO HGSC 1.15 (1.10-1.19) 5.2E-12 -- -- -- -- 
10p12.31 rs144962376 10:21878831 MLLT10 Serous 1.10 (1.06-1.13) 6.6E-09 -- -- -- -- 
17q12 rs7405776 17:36093022 HNF1B Serous 1.10 (1.07-1.14) 1.9E-10 0.482 1.16 (1.02-1.32) 0.026 0.046/0.308 
17q12 rs11651755 17:36099840 HNF1B Clear cell 0.79 (0.73-0.86) 6.8E-09 0.329 1.11 (0.97-1.28) 0.121 0.566/0.911 
17q21.31 rs7207826 17:46500673 SKAP1 Serous 1.14 (1.10-1.18) 1.2E-14 0.485 1.05 (0.92-1.19) 0.467 0.127/0.518 
17q21.32 rs1879586 17:43567337 PLEKHM1 HGSC 1.15 (1.10-1.19) 2.5E-12 0.042 1.49 (1.07-2.07) 0.018 0.012/0.144 
19p13.11 rs4808075 19:17390291 BABAM1 HGSC 1.20 (1.16-1.24) 3.3E-24 0.237 1.21 (1.04-1.41) 0.013 0.238/0.681 
19q11.21 rs688187 19:39732752 IFNL3 Mucinous 1.43 (1.33-1.53) 1.2E-22 0.384 0.97 (0.85-1.12) 0.699 0.988/0.999 
Newly identified SNPs in European ancestry OncoArray meta-analysis  
2q13 rs2165109 2:111818658 ACOXL HGSC 1.09 (1.05-1.12) 2.0E-08 0.209 0.99 (0.84-1.16) 0.890 0.020/0.192 
3q22.3 rs112071820 3:138849110 BPESC1 Mucinous 1.29 (1.20-1.37) 1.5E-13 0.328 1.14 (0.99-1.31) 0.072 0.722/0.962 
3q28 rs9870207 3:190525516 GMNC Serous borderline, LGSC 1.19 (1.12-1.27) 4.5E-08 0.364 1.08 (0.94-1.24) 0.305 0.290/0.736 
4q32.2 rs13113999 4:167187046 TLL1 Serous borderline 1.23 (1.14-1.32) 4.7E-08 0.092 0.92 (0.71-1.20) 0.551 0.109/0.482 
5q12.3 rs555025179 5:66121089 MAST4 Endometrioid 1.18 (1.11-1.26) 4.5E-08 0.415 0.96 (0.82-1.11) 0.565 0.264/0.709 
8q21.11 rs150293538 8:77320354 LINC01111 Serous borderline, LGSC 2.19 (1.65-2.90) 2.0E-09 0.005 -- -- 0.142/0.545 
8q24.21 rs9886651 8:128817883 PVT1 HGSC 1.08 (1.05-1.11) 1.9E-09 0.150 1.10 (0.92-1.33) 0.295 0.011/0.137 
9q31.1 rs320203 9:104943226 LOC105376188 Mucinous 1.29 (1.18-1.41) 1.7E-08 0.220 0.92 (0.79-1.07) 0.289 0.579/0.917 
10q24.33 rs7902587 10:105694301 LOC102724351 Serous borderline, LGSC 1.29 (1.18-1.41) 4.0E-08 0.172 1.01 (0.85-1.21) 0.881 0.470/0.866 
12q24.31 rs7953249 12:121403724 HNF1A-AS1 HGSC 1.08 (1.06-1.11) 4.5E-10 0.341 1.04 (0.91-1.19) 0.523 0.022/0.203 
18q11.2 rs8098244 18:21405553 LAMA3 Serous borderline, LGSC 1.19 (1.12-1.27) 3.9E-08 0.051 1.19 (0.87-1.63) 0.275 0.027/0.231 
22q12.1 rs6005807 22:28934313 TTC28/ LOC101929594 HGSC 1.17 (1.10-1.23) 1.2E-08 0.125 1.12 (0.92-1.36) 0.257 0.066/0.374 
SNP: single nucleotide polymorphism; Chr: chromosome; Pos: position; OR: odds ratio; CI: confidence interval; MAF: minor allele frequency; HGSC: 
high-grade serous carcinoma; LGSC: low-grade serous carcinoma. 
aPower calculations assume a disease prevalence rate of 0.01. 
* African ancestry was defined as >50% African ancestry as calculated by FastPop 
** European ancestry was defined by self-report  
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Table 3: Summary of statistically significant or suggestive results for fine mapping in African ancestry women 
of loci previously identified in GWAS of European ancestry women 
     EOC HGSCa 
Locus SNP ID Build 37 
Chr:Pos 
Nearest Gene Phenotype Number 
of SNPs 
Plotted 
Minimum SNP 
position in 
region 
Minimum 
SNP  
P-value 
Number 
of SNPs 
Plotted 
Minimum SNP 
position in 
region 
Minimum 
SNP  
P-value 
Confirmed SNPs in European ancestry OncoArray meta-analysis  
8q21.13 rs76837345 8:82668818 CHMP4C HGSC 4045 chr8:82866267 1.44E-05c 3523 chr8:82866267 3.98E-06b 
9p22.2 rs10962692 9:16915874 BNC2 HGSC 5248 chr9:16978052 2.67E-05c 4746 chr9:16986321 5.57E-05 
Newly identified SNPs in European ancestry OncoArray meta-analysis  
3q22.3 rs112071820 3:138849110 BPESC1 Mucinous 2922 chr3:138839642 3.34E-05c  --  --  -- 
10q24.33 rs7902587 10:105694301 LOC102724351 Serous borderline, LGSC 3192 chr10:105375295 3.40E-05c 2852 chr10:105300054 1.03E-03 
12q24.31 rs7953249 12:121403724 HNF1A-AS1 HGSC 3680 chr12:121113096 6.90E-05 3272 chr12:121113096 2.51E-05c 
18q11.2 rs8098244 18:21405553 LAMA3 Serous borderline, LGSC 2685 chr18:21555816 1.84E-05b 2431 chr18:21555816 6.19E-05 
EOC: epithelial ovarian cancer; HGSC: high-grade serous ovarian cancer; SNP: single nucleotide polymorphism; Chr: chromosome; Pos: position; 
LGSC: low-grade serous ovarian cancer.  
aFine mapping among HGSC was completed only for those SNPs associated with serous ovarian cancer. 
bSignificant at the Bonferroni threshold (0.05/number of SNPs plotted). 
cSignificant at the suggestive threshold (0.05/(number of SNPs plotted/3)). 
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SUPPLEMENTARY FIGURE LEGEND 
Supplementary Figure 1 
Quantile-quantile plots for the GWAS of (a) EOC and (b) HGSOC.  
Data are shown as observed and expected negative-log p-values.  
Supplementary Figure 2 
Manhattan plots for the GWAS of (a) EOC and (b) HGSOC.  
Data are shown as negative-log p-values.  
Supplementary Figure 3 
Local association plots for genetic loci reported for EOC in Table 2 near the genes: (a) AKR1C3, (b) 
LOC101927394, (c) UGT2A2, (d) WWC1.  
Data are shown as negative-log p-values.  
Supplementary Figure 4 
Local association plots for genetic loci reported for HGSOC in Table 2 near the genes: (a) FST, (b) 
MAGEC1, (c) LOC105376360, (d) PRPSAP1, (e) GABRG3, (f) LOC105377300 / GK2. 
Data are shown as negative-log p-values.  
Supplementary Figure 5 
Results of eQTL analysis in 260 ovarian tissues from AACES participants for selected SNPs from the 
GWAS of EOC and HGSOC* 
Listed below the figure: *Boxplots represent the distribution of measured expression versus genotype (rounded to the 
nearest whole number for imputed dosage variables). P-values are reported from linear models with covariate 
adjustment for age and two principal components of ancestry. 
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Supplementary Table 1: Descriptive statistics for study participants 
 EOC HGSOC  
Cases Controls Total Cases Controls Total 
Study Sites n (%) n (%) n (%) n (%) n (%) n (%) 
AAS – African American Cancer Epidemiology Study 467 (61.9) 563 (45.6) 1030 (51.8) 349 (65.0) 563 (45.6) 912 (51.5) 
BEL – Belgium Ovarian Cancer Study 0 (0.0) 2 (0.2) 2 (0.1) 0 (0.0) 2 (0.2) 2 (0.1) 
BVU – The BioVU DNA Repository 8 (1.1) 98 (7.9) 106 (5.3) 4 (0.7) 98 (7.9) 102 (5.8) 
CAM – Cancer Research UK, Cambridge Research Institute 1 (0.1) 0 (0.0) 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 
DKE – Duke University Clinic 7 (0.9) 0 (0.0) 7 (0.4) 3 (0.6) 0 (0.0) 3 (0.2) 
DOV – Diseases of the Ovary and their Evaluation 7 (0.9) 27 (2.2) 34 (1.7) 4 (0.7) 27 (2.2) 31 (1.8) 
HAW – Hawaii Ovarian Cancer Study 0 (0.0) 3 (0.2) 3 (0.2) 0 (0.0) 3 (0.2) 3 (0.2) 
HOP – Hormones and Ovarian Cancer Prediction 16 (2.1) 21 (1.7) 37 (1.9) 10 (1.9) 21 (1.7) 31 (1.8) 
LAX – Women's Cancer Program at the Samuel Oschin 
Comprehensive Cancer Institute 
18 (2.4) 0 (0.0) 18 (0.9) 15 (2.8) 0 (0.0) 15 (0.9) 
MAY – Mayo Clinic Ovarian Cancer Case-Control Study 3 (0.4) 5 (0.4) 8 (0.4) 2 (0.4) 5 (0.4) 7 (0.4) 
MEC – Multiethnic Cohort Study 10 (1.3) 13 (1.1) 23 (1.2) 6 (1.1) 13 (1.1) 19 (1.1) 
MOF – Moffitt Cancer Center Ovarian Cancer Study 16 (2.1) 14 (1.1) 30 (1.5) 13 (2.4) 14 (1.1) 27 (1.5) 
MSK – Memorial Sloan Kettering Cancer Center 8 (1.1) 20 (1.6) 28 (1.4) 8 (1.5) 20 (1.6) 28 (1.6) 
NCO – North Carolina Ovarian Cancer Study 108 (14.3) 160 (13.0) 268 (13.5) 76 (14.2) 160 (13.0) 236 (13.3) 
NEC – New England Case-Control Study of Ovarian Cancer 6 (0.8) 5 (0.4) 11 (0.6) 6 (1.1) 5 (0.4) 11 (0.6) 
NHS – Nurses’ Health Study I and II 3 (0.4) 0 (0.0) 3 (0.2) 3 (0.6) 0 (0.0) 3 (0.2) 
NOR – University of Bergen, Haukeland University Hospital, Norway 1 (0.1) 0 (0.0) 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 
NTH – Nijmegen Ovarian Cancer Study 1 (0.1) 0 (0.0) 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 
ORE – Oregon Ovarian Cancer Registry 1 (0.1) 0 (0.0) 1 (0.1) 1 (0.2) 0 (0.0) 1 (0.1) 
OVA – Ovarian Cancer in Alberta and British Columbia 1 (0.1) 0 (0.0) 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 
PLC –Prostate-Lung-Colorectal and Ovarian Cancer Screening Trial 5 (0.7) 85 (6.9) 90 (4.6) 2 (0.4) 85 (6.9) 87 (4.9) 
RMH – Royal Marsden Hospital Ovarian Cancer Study 1 (0.1) 0 (0.0) 1 (0.1) 1 (0.2) 0 (0.0) 1 (0.1) 
RPC – Roswell Park Cancer Institute Ovarian Cancer Cohort 4 (0.5) 0 (0.0) 4 (0.2) 3 (0.6) 0 (0.0) 3 (0.2) 
SEA – UK Studies of Epidemiology and Risk Factors in Cancer 
Heredity (SEARCH) Ovarian Cancer Study 
2 (0.3) 1 (0.1) 3 (0.2) 1 (0.2) 1 (0.1) 2 (0.1) 
SIS – The Sister Study 8 (1.1) 131 (10.6) 139 (7.0) 3 (0.6) 131 (10.6) 134 (7.6) 
SOC – Southampton Ovarian Cancer Study 1 (0.1) 0 (0.0) 1 (0.1) 0 (0.0) 0 (0.0) 0 (0.0) 
STA – Genetic Epidemiology of Ovarian Cancer 12 (1.6) 45 (3.6) 57 (2.9) 4 (0.7) 45 (3.6) 49 (2.8) 
UCI – UC Irvine Ovarian Cancer Study 0 (0.0) 2 (0.2) 2 (0.1) 0 (0.0) 2 (0.2) 2 (0.1) 
UHN – Princess Margaret Cancer Centre 4 (0.5) 0 (0.0) 4 (0.2) 2 (0.4) 0 (0.0) 2 (0.1) 
UKO – UK Ovarian Cancer Population Study 4 (0.5) 10 (0.8) 14 (0.7) 2 (0.4) 10 (0.8) 12 (0.7) 
USC – Los Angeles County Case-Control Studies of Ovarian Cancer 31 (4.1) 30 (2.4) 61 (3.1) 18 (3.4) 30 (2.4) 48 (2.7) 
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WMH – Westmead Institute for Cancer Research – Westmead 
Hospital 
1 (0.1) 0 (0.0) 1 (0.1) 1 (0.1) 0 (0.0) 1 (0.1) 
TOTAL 755 1235 1990 537 1235 1772 
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Supplementary Table 2: Bayesian False-Discovery Probabilities for Ovarian Cancer GWAS SNPs in women of African ancestry  
Subtype Nearest Gene SNP ID (Effect / other allele) 
OR 
 (95% CI) P-value BFDP1/1K BFDP1/10K 
EOC 
AKR1C3 rs4525119 (T/C) 0.70  (0.61-0.81) 4.9 x 10
-7
 0.08 0.49 
LOC101927394 rs7643459* (T/G) 1.40  (1.22-1.60) 8.4 x 10
-7
 0.05 0.33 
UGT2A2 rs4286604 (A/G) 0.69  (0.59-0.80) 8.5 x 10
-7
 0.05 0.34 
WWC1 rs142091544 (T/C) 
3.22 
(2.02-5.13) 9.4 x 10
-7 0.08 0.47 
HGSOC 
FST rs37792 (G/A) 0.65  (0.55-0.76) 6.0 x 10
-8
 0.004 0.04 
MAGEC1 rs57403204 (G/A) 2.62  (1.83-3.76) 1.7 x 10
-7 0.01 0.13 
LOC105376360 rs79079890 (G/T) 3.20  (2.05-4.99) 3.0 x 10
-7 0.03 0.25 
PRPSAP1 rs66459581 (A/AC) 
1.63  
(1.35-1.97) 5.1 x 10
-7 0.02 0.19 
GABRG3 rs116046250 (G/T) 
2.95  
(1.92-4.54) 8.7 x 10
-7 0.07 0.44 
LOC105377300 / 
GK2 
rs192876988 
(C/T) 
3.01  
(1.94-4.68) 9.2 x 10
-7 0.08 0.47 
BFDP=Bayesian false-discovery probability; the subscripted number is the level of prior probability 
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Supplementary Table 3: Genes targeted for eQTL analysis within the region of ten EOC- and HGSOC-associated SNPs 
Subtype SNP ID 
Build 37  
Chr:Pos Nearest gene Genes within 100kb Genes at 100-500kba 
EOC 
rs4525119 10:5091954 AKR1C3 AKR1C3, AKR1C1, AKR1C2  
rs7643459 3:8004828 LOC101927394 LOC101927394  
rs4286604 4:70442165 UGT2A2 UGT2B4, UGT2A2, UGT2A1  
rs142091544 5,167714000 WWC1 WWC1, TENM2  
HGSOC 
rs37792 5:52644647 FST  ITGA1, ITGA2, FST, NDUFS4 
rs57403204 X:141078552 MAGEC1 MAGEC1, MAGEC3  
rs79079890 10:3684148 LOC105376360 LOC105376360  
rs66459581 17:74355264 PRPSAP1 
PRPSAP1, UBALD2, 
QRICH2, U6, SPHK1,UBE2D, 
AANAT 
 
rs116046250 15:27231950 GABRG3 GABRG3, GABRB3, GABRA6,  AK124673 
 
rs192876988 4:80297251 GK2 GK2, NAA11, LOC100505875  
 aGenes in the 100-500kb range are reported and considered in eQTL analysis only for variants with no genes within 100kb. 
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Supplementary Table 4: Summary of genetic association for selected SNPs identified in GWAS of EOC and HGSOC with breast cancer in African 
American individuals from the AABC study 
Nearest Gene 
SNP ID 
(Effect / 
Other allele) 
Build 37 
Chr:Pos EAF 
Breast cancer - all ER positive ER negative 
OR ( 95% CI) P-value OR (95% CI) P-value OR (95% CI) P-value 
AKR1C3 rs4525119 (T/C) 10:5091954 0.328 
1.07 
(0.99,1.16) 0.098 
1.02 
(0.93,1.13) 0.621 
1.11 
(1.00,1.24) 0.058 
LOC101927394 rs7643459 (T/G) 3:8004828 0.377 
1.05 
(0.97,1.13) 0.232 
1.02 
(0.93,1.12) 0.622 
1.13 
(1.01,1.26) 0.029 
UGT2A2 rs4286604 (A/G) 4:70442165 0.279 
0.94 
(0.86,1.02) 0.142 
0.93 
(0.84, 1.04) 0.205 
0.96 
(0.85,1.09) 0.551 
WWC1 rs142091544 (T/C) 5:167714000 0.040 
1.07 
(0.87, 1.31) 0.530 
0.87 
(0.67, 1.14) 0.314 
1.55  
(1.19, 2.02) 0.001 
FST rs37792 (G/A) 5:52644647 0.341 
0.96 
(0.89, 1.04) 0.424 
0.97 
(0.88,1.07) 0.578 
0.97 
(0.87, 1.09) 0.621 
MAGEC1 rs57403204 (G/A) X:141078552 0.051 
0.93 
(0.77, 1.12) 0.424 
0.89 
(0.71, 1.12) 0.329 
0.97 
(0.74, 1.25) 0.813 
LOC105376360 rs79079890 (G/T) 10:3684148 0.035 
1.22 
(0.99,1.50) 0.066 
1.21 
(0.95,1.55) 0.125 
1.12 
(0.83,1.52) 0.449 
PRPSAP1 rs66459581 (A/AC) 17:74355264 0.228 
1.01 
(0.92,1.10) 0.890 
0.89 
(0.80,1.00) 0.054 
1.12 
(0.99,1.28) 0.081 
GABRG3 rs116046250 (G/T) 15:27231950 0.045 
0.87 
(0.71,1.06) 0.176 
0.88 
(0.69,1.12) 0.306 
0.83 
(0.62,1.10) 0.195 
LOC105377300 
/ GK2 
rs192876988 
(C/T) 4:80297251 0.040 
1.19 
(0.96,1.47) 0.105 
1.32 
(1.03,1.69) 0.027 
1.02 
(0.75,1.39) 0.883 
SNP: single nucleotide polymorphism; EAF: effect allele frequency; OR: odds ratio; CI: confidence interval 
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Supplementary Table 5: Summary of genetic association for selected SNPs identified in GWAS of EOC and HGSOC with prostate cancer in 
African American individuals from the AAPC study 
Nearest Gene 
SNP ID 
(Effect / 
Other allele) 
Build 37 
Chr:Pos EAF OR (95% CI) P-value 
AKR1C3 rs4525119 (T/C) 10:5091954 0.328 1.03 (0.97, 1.10) 0.304 
LOC101927394 rs7643459 (T/G) 3:8004828 0.371 1.07 (1.01, 1.13) 0.034 
UGT2A2 rs4286604 (A/G) 4:70442165 0.264 1.08 (1.01, 1.15) 0.025 
WWC1 rs142091544 (T/C) 5:167714000 0.036 1.11 (0.94, 1.32) 0.197 
FST rs37792 (G/A) 5:52644647 0.325 0.99 (0.93, 1.03) 0.685 
MAGEC1 rs57403204 (G/A) X:141078552 0.056 0.98 (0.89, 1.09) 0.754 
LOC105376360 rs79079890 (G/T) 10:3684148 0.037 0.96 (0.82, 1.13) 0.646 
PRPSAP1 rs66459581 (A/AC) 17:74355264 0.230 1.03 (0.96, 1.11) 0.363 
GABRG3 rs116046250 (G/T) 15:27231950 0.042 0.93 (0.80, 1.08) 0.365 
LOC105377300 
/ GK2 
rs192876988 
(C/T) 4:80297251 0.043 0.95 (0.81, 1.12) 0.567 
 SNP: single nucleotide polymorphism; EAF: effect allele frequency; OR: odds ratio; CI: confidence interval 
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Supplementary Table 6: Summary of results for fine mapping in African ancestry women of loci previously identified in GWAS of European 
ancestry women 
     EOC HGSCa 
Locus SNP ID Build 37 
Chr:Pos 
Nearest Gene Phenotype Number 
of SNPs 
Plotted 
Minimum SNP 
position in 
region 
Minimum 
SNP  
P-value 
Number 
of SNPs 
Plotted 
Minimum SNP 
position in 
region 
Minimum 
SNP  
P-value 
Confirmed SNPs in European ancestry OncoArray meta-analysis  
1p34.3 rs58722170 1:38096421 RSPO1 Serous 3078 chr1:37917469 2.91E-04 2685 chr1:37917469 3.38E-04 
2q14.1 rs752590 2:113972945 PAX8 Mucinous 3615 chr2:114298849 2.31E-03  --  --  -- 
2q31.1 rs711830 2:177037311 HOXD3 Mucinous 3171 chr2:1177037311 2.23E-03  --  --  -- 
2q31.1 rs6755777 2:177043226 HAGLR Serous 3175 chr2:177326682 2.23E-03 2775 chr2:177442640 2.49E-03 
3q25.31 rs62274041 3:156435640 TIPARP HGSC 3204 chr3:156252180 2.01E-03 2863 chr3:156204177 2.37E-03 
5p15.33 rs10069690 5:1279790 TERT Serous 5037 chr5:949207 9.57E-04 4497 chr5:892204 7.97E-04 
5p15.33 rs7705526 5:1285974 TERT Serous borderline 5005 chr5:949207 9.57E-04 4464 chr5:892204 7.97E-04 
8q21.13 rs76837345 8:82668818 CHMP4C HGSC 4045 chr8:82866267 1.44E-05c 3523 chr8:82866267 3.98E-06b 
8q24.21 rs1400482 8:128529685 LINC00824 Serous 4414 chr8:128619531 3.51E-04 3897 chr8:128762529 1.86E-03 
9p22.2 rs10962692 9:16915874 BNC2 HGSC 5248 chr9:16978052 2.67E-05c 4746 chr9:16986321 5.57E-05 
9q34.2 rs8176685 9:136138766 ABO HGSC 3968 chr9:136075407 5.07E-04 3472 chr9:136267149 3.17E-04 
10p12.31 rs144962376 10:21878832 MLLT10 Serous 2514 chr10:21978590 4.13E-03 2162 chr10:22035324 7.73E-03 
17q12 rs7405776 17:36093022 HNF1B Serous 2787 chr17:36195231 5.44E-03 2324 chr17:36113300 7.82E-04 
17q12 rs11651755 17:36099840 HNF1B Clear cell 2778 chr17:36195231 5.44E-03  --  --  -- 
17q21.31 rs7207826 17:46500673 SKAP1 Serous 2827 chr17:46807761 6.43E-04 2572 chr17:46215732 8.18E-04 
17q21.32 rs1879586 17:43567337 PLEKHM1 HGSC 3735 chr17:43954416 1.31E-04 3370 chr17:43945726 1.44E-04 
19p13.11 rs4808075 19:17390291 BABAM1 HGSC 9100 chr19:17395213 1.77E-04 4077 chr19:17088458 3.07E-04 
19q11.21 rs688187 19:39732752 IFNL3 Mucinous 8360 chr19:39684764 1.21E-04  --  -- -- 
Newly identified SNPs in European ancestry OncoArray meta-analysis  
2q13 rs2165109 2:111818658 ACOXL HGSC 2172 chr2:111595642 6.87E-03 1951 chr2:111832215 1.47E-02 
3q22.3 rs112071820 3:138849110 BPESC1 Mucinous 2922 chr3:138839642 3.34E-05c  --  --  -- 
3q28 rs9870207 3:190525516 GMNC Serous borderline, LGSC 4647 chr3:190657915 3.73E-03 4081 chr3:190839089 3.34E-03 
4q32.2 rs13113999 4:167187046 TLL1 Serous borderline 4879 chr4:167492545 4.71E-03 4252 chr4:166876033 8.01E-04 
5q12.3 rs555025179 5:66121089 MAST4 Endometrioid 3720 chr5:65907851 5.91E-03  --  --  -- 
8q21.11 rs150293538 8:77320354 LINC01111 Serous borderline, LGSC 3305 chr8:77354021 1.17E-04 2883 chr8:77320354 2.01E-04 
8q24.21 rs9886651 8:128817883 PVT1 HGSC 4449 chr8:129036159 2.67E-04 3962 chr8:129093793 1.52E-03 
9q31.1 rs320203 9:104943226 LOC105376188 Mucinous 4927 chr9:105237170 1.49E-03  --  --  -- 
10q24.33 rs7902587 10:105694301 LOC102724351 Serous borderline, LGSC 3192 chr10:105375295 3.40E-05c 2852 chr10:105300054 1.03E-03 
12q24.31 rs7953249 12:121403724 HNF1A-AS1 HGSC 3680 chr12:121113096 6.90E-05 3272 chr12:121113096 2.51E-05c 
18q11.2 rs8098244 18:21405553 LAMA3 Serous borderline, LGSC 2685 chr18:21555816 1.84E-05b 2431 chr18:21555816 6.19E-05 
22q12.1 rs6005807 22:28934313 TTC28/ LOC101929594 HGSC 2513 chr22:29126617 1.27E-02 2066 chr22:29073209 1.56E-02 
EOC: epithelial ovarian cancer; HGSC: high-grade serous ovarian cancer; SNP: single nucleotide polymorphism; Chr: chromosome; Pos: position; LGSC: low-grade serous ovarian cancer.  
aFine mapping among HGSC was completed only for those SNPs associated with serous ovarian cancer. 
bSignificant at the Bonferroni threshold (0.05/number of SNPs plotted). 
cSignificant at the suggestive threshold (0.05/(number of SNPs plotted/3)). 
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Supplementary Table 7: Summary of results for fine mapping in European ancestry women of loci identified in our GWAS of African ancestry 
women 
 EOC HGSOC 
Gene SNP ID Build 37  Chr:Pos 
Number 
of SNPs 
plotted 
Minimum SNP 
position in 
region 
Min SNP 
p-value 
Number 
of SNPs 
plotted 
Minimum SNP 
position in 
region 
Min SNP 
p-value 
AKR1C3 rs4525119  10:5091954 6105 chr10:5341275 2.44E-03 -- -- -- 
LOC101927394 rs7643459  3:8004828 5466 chr3:8268351 1.12E-03 -- -- -- 
UGT2A2 rs4286604  4:70442165 5542 chr4:70592790 1.14E-05a -- -- -- 
WWC1 rs142091544 5:167714000 3761 chr5:167857657 1.74E-04 -- -- -- 
FST rs37792  5:52644647 -- -- -- 4416 chr5:52332701 3.94E-05 
MAGEC1 rs57403204  X:141078552 -- -- -- 3389 chrX:141078552 1.78E-04 
LOC105376360 rs79079890  10:3684148 -- -- -- 4899 chr10:3463140 2.24E-04 
PRPSAP1 rs66459581  17:74355264 -- -- -- 4025 chr17:74420211 3.74E-04 
GABRG3 rs116046250  15:27231950 -- -- -- 3885 chr15:27240688 5.16E-04 
LOC105377300/GK2 rs192876988  4:80297251 -- -- -- 3443 chr4:80297251 5.76E-04 
aSignificant at the suggestive threshold (0.05/(number of SNPs plotted/3)). 
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Manichaikul et al., Supplementary Figure 1 
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Manichaikul et al., Supplementary Figure 2 
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